Objective:

To evaluate whether the addition of immune checkpoint inhibitors (ICIs) to induction chemotherapy improves outcomes in HPV-negative oropharyngeal squamous cell carcinoma (OPSCC), and whether efficacy differs by primary tumor subsite.

Approach:

Key Findings:

• Clarify that differences in PFS and OS were not statistically significant.
• Remove vague phrases like 'numerically improved' and specify the context of the findings.

Interpretation:

Remove unsupported claims about potential benefits.

Limitations:

• Retrospective design may introduce bias.
• Small sample size limits generalizability.
• Statistical significance was not achieved for overall cohort outcomes.

Conclusion:

Rephrase to avoid suggesting potential benefits not explicitly stated in the source.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.